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Recombinant Bovine Somatotropin (BST) has been the subject of controversy 
for over five years. Most if not all of the potential scientific, political, economic, 
and ethical risks and benefits associated with widespread use of the compound 
are well-documented. Yet, as is evidenced by the continuing stream of profes-
sional journal and newspaper articles, and workshops and symposia around 
the world, the issues associated with BST remain topics of heated debate. There 
are several reasons for this. That BST is one of the first commercially-feasible 
products from biotechnology is certainly part of the case. There are, however, 
many more important dimensions to “The Case of BST” than its biotechnology 
connection.
One important condition in this regard is the larger society’s “philosophy of 
technology’ which serves to guide both individual and institutional decisions. 
One such philosophy - to be referred to as “productionism”—has come to 
dominate decisions about both agriculture and agricultural research. Although 
there are strong historical as well as ethical reasons behind the productionist 
idea, this view has come under increasing philosophical (as well as political) at-
tack. It is at this philosophical level that the major ethical concerns per-
taining to the case to BST are raised. For, in the face of ethical challenges to 
productionism, we, as individuals and as a society, must again decide whether 
“more technology" and “more products” are to remain social and individual 
goals. For many social analysts, and in many governmental accounts of future 
possibilities for our society’s technological mode, there seems to be an assump-
tion that particular kinds of changes are inevitable. The focus on “trends,” 
“tracks” and “outcomes” suggests that particular kinds of change will occur.
As important as the notion of choice is in the analysis of technical change, it is 
a mistake to think that all particular technical changes are the result of planning 
or conscious design. Technical changes occur for a variety of reasons, motives 
and beliefs, not all of which are calculated, planned and informed. The notion 
of a “technology treadmill” is understandable in this light. In effect, because of 
our prior decisions and the decisions of others, we must choose technical 
change. As the stream of new technologies continues, we will continue to have 
to make those choices.
At the individual level, “the ethics of technique” pertains to the actual prac-
tice of using a tool or technique. The ethics associated with change in technique 
at this level are principles governing learning about and monitoring the use of
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the new tool or strategy, so that bad consequences are avoided.
“Technical ethics” also covers the decisions groups of individuals make to 
adopt techniques in the first place: is the choice of a particular “new” technique 
or tool justifiable from the point of view of the array of ethical values which sur-
face in an individual’s interactions and connections with others in a larger com-
munity?
A third dimension of the ethics of technique involves the decisions groups of 
individuals make to allow or legitimize the adoption of new techniques on a 
larger societal scale. Decisions of this sort are made by “invisible hands” or “vis-
ible hands.” For a variety of ethical reasons (including freedom of choice), mar-
kets are judged to produce the“best results”: markets deliver what consumers 
want, for whatever reasons they want, including ethical (and unethical) reasons.
Markets only deliver or governments only authorize techniques or products 
which have already been at least conceptualized. The fourth dimension of 
“technical ethics” thus concerns the decisions individuals or groups make with 
respect to research on and development of new techniques and alternative ways 
of doing things. The judgement that a particular technique or tool should be 
developed in the first place is certainly made in the hope or expectation that it 
will be “induced” into a political-economic system once developed. “Eco-
nomic” interests in the success or profitability of the new technique undoubt-
edly predominate. The value-context (e.g., “mission”) of research institutions 
themselves is also relevant, as is whether or not the decisions are made in pri-
vate, or in the public arena. This reflects consideration of ethical values sub-
scribed to by the larger society: toward what techniques are potential consum-
ers and the larger public disposed?
The last and broadest dimension of the “ethics of technical change” pertains 
to the larger society’s beliefs and dispositions toward new techniques. What dic-
tates our willingness to accept, promote, certify, adopt and use new tools, tech-
nologies, or techniques? What principles explicitly or implicitly lead us to ratify 
particular kinds of technical changes? A basic question is: upon what principles 
and values do we j udge even our basic philosophy of technology to be right or 
good?
The case of BST is a good “ethics case” with regard to technical change, for it 
includes all of the dimensions of individual and group decision-making, insti-
tutional legitimacy, and fundamental philosophy, although the last may be less 
than transparent at first sight.
The case of BST is standardly invoked in discussions of the ethics of the “new 
biotechnology”, and genetic engineering in particular. This can be misleading. 
While BST is a product of procedures which involve genetic engineering, most
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of the issues associated with the case of BST are independent of its biotech-
nology connection. Of course, if there are major ethical problems associated 
with biotechnology per se, recombinant BST is not significantly different from 
“natural” BST harvested from the pituitary glands of cows. Unless we ethically 
reject all such “bioproducts,” BST remains but a “new technology” in the broad-
est sense of that term. Ethical principles apply to the case of BST just as they ap-
ply to other new technologies, e.g., computer software.
The “ethics of technique” is raised initially in connection with the question of 
whether there is a right way and a wrong way to use BST. Analysts of BST have 
repeatedly noted that a significant change in “management” is associated with 
BST use: individualized dosages, careful monitoring, etc. This is significant 
from the point of view of economics and also from the point of view of ethics: 
BST carries with it some “rules.”
The major ethical question associated with individual choice about BST is, 
however, whether there really is a choice. It may be that the economic and social 
situation in which farmers find themselves unfairly limit their opportunities for 
choosing alternative techniques. However, it would appear that farmers do have 
a choice not to use BST. That they choose to do so suggest that they have ac-
cepted the conditions historically prior to and philosophically behind the intro-
duction of BST.
Most of the literature pertaining to the case of BST has focused on the “social 
ethics” features of BST legitimation and creation. The question of the “market-
ing of BST” and the responsibility of federal government agencies (USDA, EPA, 
FDA), state governments (e.g., Wisconsin, Minnesota) and the courts in decid-
ing the legitimacy of the diffusion of this technique is of course a major element 
in this story. The conflict-ridden interactions of people, as well as the economic 
and ethical values undergirding the conflicts pertain to two basic questions:
Why BST? Why not BST?
In the political sphere and in the larger public forum, the “case against BST” 
has been pressed by coalitions of dairy farmers, animal rights activists, the 
Foundation on Economic Trends, and most recently, the Consumer’s Union. 
The arguments range from those highlighting the likely negative socio-eco-
nomic effects on classes of dairy farmers, to indictments of the potential nega-
tive human and animal health effects, to larger questions about society’s “per-
mitting” biotechnologically-generated products of uncertain social, economic, 
and environmental worth. Across the stage, the National Institutes of Health, 
the developers of BST, and some producers’ organizations, argue the domestic 
and international economic validity as well as human and animal safety of the 
compound. One senses at times that the future of farming, governmental legiti-
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macy, scientific freedom and progress and the survival of corporate America are 
all on the line. Interestingly, it has been stated that had the creators of BST 
known how it would be received and handled by governments and the creators 
themselves, an alternative such as porcine somatotropin (PST) would have 
been promoted in the first place. However, as some social scientists and ethicists 
have noted, it is not simply a strategic error in not considering the potentially 
controversial consequences of research and product-development, it is an ethi-
cal one as well, in failure to have considered some farmers’, animal activists, and 
the larger consuming public’s perceptions and values.
Serving agriculture through productionism, rationalizing agriculture 
through “big science” and emphasizing efficiency (under a narrow economic 
definition of terms) have remained the reigning mission and strategy of public 
agricultural research, as well as the dominant direction of private, corporate re-
search. American consumers have benefitted by having the lowest food-to-in- 
come ratio in the world. The technologies that have been developed, from bio- 
technologically-engineered plant varieties to agrichemicals to computer-driven 
irrigation systems and sophisticated post-harvest transport, wholesaling and 
retailing systems-and now BST -are heralded as having allowed agricultural-
ists to all-but-overcome the inherent risks involved in farming. There is little 
doubt that the spread of these research products into less-developed nations, 
and the ensuing “Green Revolution” which transformed not only agriculture 
but whole societies, have produced great benefits for many people.
In our case study, a critique of productionism underlies the challenge to BST. 
It is as well a critique of technophilia, and perhaps to the utilitarian ethical phi-
losophy which provides it the best justification. The challenge is far from 
univocal or even articulate in the actual public arena, coming as it does from an 
eclectic collection of environmentalists, family-farm advocates, the Foundation 
on Economic Trends, and the like. Nevertheless, it is there: Why not BST? The 
intriguing thing about the “case of BST” is how quickly and deeply the ethical 
question of “how to use” BST leads to “why new techniques,” ultimately to, 
what kind of people are we and what kind of society do we want?
Over and above agriculture and agricultural research, many features of 
“modern” society continue to be challenged from a diverse array of thinkers. 
Productionism, and productionist-oriented technical change have done won-
derful things, but at great individual and societal expense. More is no longer 
better, if it ever were.
The anti-productionist critique may overstate the case. Moreover, in the con-
text of an appraisal of “the case of BST” the issue may seem grossly out of place. 
BST is, after all, only a single product, affecting only a single, small sector of a 
significant but hardly history-moving industry.
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